SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K was filed by BioSig Technologies, Inc. on May 2, 2024. The report discloses a corporate governance event under Item 5.02 regarding the appointment of a new director. The company is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BSGM.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board composition changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of Mr. Chris Baer as a director on the Board of Directors, effective May 2, 2024. Mr. Baer brings over 25 years of commercial experience in the medical device sector, including roles at CDL Nuclear Technologies, Impulse Dynamics, and St Jude Medical/Abbott. He will serve on the audit, nominating, and compensation committees.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. No risks, contingencies, or unusual items were disclosed in this specific report. The Board confirmed there are no undisclosed arrangements or transactions involving Mr. Baer requiring disclosure under Item 404(a) of Regulation S-K.
Key Facts for Investor Verification
- Verify the effective date of Mr. Chris Baer's appointment (May 2, 2024).
- Confirm Mr. Baer's committee assignments (Audit, Nominating, and Compensation).
- Note that this filing does not impact the company's current financial statements or debt obligations.
- Check for any subsequent filings regarding the term expiration of the new director.